Dementia and Alzheimer Disease

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 16, 2020.

The assistant professor of neurology and neuroscience at Mount Sinai Medical Center detailed the findings of a recent pilot trial of riluzole in Alzheimer disease she and colleagues conducted.

To date, the connection between vascular dysfunction and tau pathology and how it affects cognition has not been well understood.

The Cleveland Clinic researcher details a study that will use biomarkers to develop a predictive model to identify individuals with Parkinson disease who may develop dementia.

The assistant professor of neurology and neuroscience at Mount Sinai Medical Center discussed the literature that influenced a pilot trial of riluzole in Alzheimer disease.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending October 10, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 9, 2020.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Costantino Iadecola, MD.

Phase 2 results demonstrated proof-of-concept for treatment with neflamapimod, suggesting the need for a phase 3 study in the coming future.

The 5-year grant will support a research project that will use biomarkers to develop a predictive mathematical model to identify specific individuals with Parkinson disease who may develop dementia.

James Leverenz, MD, director of the Lou Ruvo Center for Brain Health at Cleveland Clinic, discussed the strides made in Alzheimer disease research and the importance of diversity in research populations.

Linear mixed effects models revealed that anticholinergic medications predicted a steeper slope of decline in memory and language with effects exacerbated in individuals with Alzheimer disease risk factors.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending October 2, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 2, 2020.

Jonathan Graff-Radford, MD, neurologist at Mayo Clinic, discussed how recent diagnostic advancements have propelled research efforts into uncharted territory.

The neurologist at Mayo Clinic detailed promising diagnostic tools, including the revelation of blood tests in patients with Alzheimer disease.

The funding will offer additional benefit for the HABLE and HABLE-AT(N) studies with the ability to better classify and categorize participants into groups by dementia type and disease stage.

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine discussed the role amyloid plays in various types of Alzheimer disease and its impact on vascular dysfunction.

The vaccine could be given therapeutically to individuals living with a diagnosis of AD to inhibit further disease progression.

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine discussed the role amyloid plays in various types of Alzheimer disease and its impact on vascular dysfunction.

Neurology News Network for the week ending September 26, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 25, 2020.

The findings suggest that this insomnia phenotype is a more biologically severe form of the disorder associated with cardiovascular, cerebrovascular, and neurocognitive morbidity.